Researchers at Washington University School of Medicine and the Weizmann Institute reported engineered immune cells that target and reduce toxic brain proteins linked to neurodegeneration. Using CAR‑T–style approaches directed at disease‑associated proteins, the team demonstrated target engagement and reduction of pathogenic protein burdens in experimental models and published results in Proceedings of the National Academy of Sciences. The study repurposes CAR‑T immunotherapy concepts for neurodegenerative disease and highlights delivery, on‑target specificity and CNS safety as key translational hurdles. Investigators described advances in cell engineering and targeting that may inform early clinical‑stage programs aiming to clear pathological proteins in Alzheimer’s and related disorders.